Deinove: industrial production of carotenoids begins, animal testing results due

By Jane Byrne contact

- Last updated on GMT

© GettyImages/EtiAmmos
© GettyImages/EtiAmmos

Related tags: Animal nutrition, Antioxidant, Metabolism

French biotech company, Deinove, says the results of extensive in vivo efficacy and bioavailability trials on its bacteria derived carotenoid compounds in poultry and fish diets will be released next month.

In animal feed applications, the ideas is that those compounds would be used mainly for pigmentation of skin and yolks but they do have nutritional value as well in terms of antioxidant functionality, the Montpellier headquartered company told us earlier this year.

The fish and poultry trials were run to replicate earlier findings but in a larger cohort of animals. They form part of a strategic project Deinove collaborates in with French agribusiness group, Avril, and through an initiative in the US with Flint Hills Resources.  

Yesterday [20 December] also saw Deinove, which was set up to discover, develop, and produce high-value compounds from rare bacteria, notably from the Deinococcus genus, announce the launch of the industrial production of its first carotenoid.  

However, CEO of Deinove, Emmanuel Petiot, told us this commercial phase is only targeting food supplement and cosmetic applications, not animal nutrition; the scale up involves the use of a toll manufacturer – SAS Pivert.

The company said it has developed an optimized process in terms of performance and robustness on a 20-liter scale.

Chinese patent

Earlier this year, Deinove reported that its first patent focusing on the use of the bacteria, Deinococcus, for animal nutrition had been issued in China.

Petiot said then that the patent demonstrated the progress it has made in the animal nutrition sector in the past three years.

“China is the world's largest producer of livestock, it is therefore essential that we can eventually market our innovations there with all the necessary protections. However, this patent is intended to be issued in all other major territories,” ​he added.

Deinove has nearly 160 international patent applications. 

The company, which has been listed on the Alternext since April 2010, cites two key assets in terms of its development plan: its strain bank with 6,000 rare bacteria that have not yet been exploited and its genetic, metabolic and fermentation engineering platform that enables it to customize these natural micro-factories. 

Related news

Show more

Related products

show more

5 TIPS FOR CHOOSING A GOOD SELENIUM ENRICHED YEAST

5 TIPS FOR CHOOSING A GOOD SELENIUM ENRICHED YEAST

Lallemand Animal Nutrition | 06-May-2020 | Data Sheet

When talking about organic selenium, the three words “bioavailability, quality, and price” are always mentioned within the first three sentences.

Modern molecules to support antibiotic reduction

Modern molecules to support antibiotic reduction

Perstorp | 10-Feb-2020 | Technical / White Paper

Though solutions based on organic acids have been used for various benefits in feed and feed raw material production for decades, the developments are...

Galli Crunch, developed to be better

Galli Crunch, developed to be better

Nuscience Group | 28-Oct-2019 | Technical / White Paper

In commercial hatcheries, chicks hatch over a wide hatching window, depriving them from feed and water for up to 72 hours.

Related suppliers

Follow us

Products

View more

Webinars